Entera Bio

Company Overview

Snapshot

Founded in September 2009, Entera Bio operates with 11–50 employees. The company has raised a total of $58.9M across 7 funding rounds from 7 investors. Entera Bio went public on NASDAQ in July 2018.

Business overview

Entera Bio is a biotechnology company focused on the oral delivery of large molecules and biologics. The company's proprietary technology enhances the absorption of these compounds in the gastrointestinal tract, addressing challenges related to degradation and poor absorption. Entera Bio is developing first-in-class, daily tablet protein and peptide replacement therapies for patients managing chronic diseases, aiming to provide injection-free treatment options. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, Drug Delivery, and Drugs Discovery & Development, serving patients in the healthcare and life sciences industries.

Strategic signal

Entera Bio is actively advancing its pipeline of oral peptide programs, with recent news indicating positive clinical data and upcoming presentations. In May 2026, the company announced that its EB613, a first-in-class oral PTH(1-34) anabolic for osteoporosis, was selected for a late-breaking oral presentation at ENDO 2026, alongside other oral peptide pipeline data. This highlights the company's continued progress in clinical development and its commitment to showcasing innovative solutions for chronic diseases, signaling potential for future product approvals and market expansion.

Company Intelligence Q&A

What is Entera Bio's primary focus?

Entera Bio specializes in the oral delivery of large molecules and biologics, developing proprietary technology to enhance their absorption in the gastrointestinal tract for therapeutic purposes.

When did Entera Bio go public?

Entera Bio went public on NASDAQ in July 2018.

What was a significant recent development for Entera Bio's EB613 program?

In May 2026, Entera Bio's EB613, a first-in-class oral PTH(1-34) anabolic for osteoporosis, was selected for a late-breaking oral presentation at the ENDO 2026 Annual Meeting.

What was the outcome of Entera Bio's collaboration with OPKO Biologics?

In September 2023, Entera Bio announced a collaboration with OPKO Biologics to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes.

What did Entera Bio report regarding its EB613 Phase 3 program in November 2023?

In November 2023, Entera Bio reported a key milestone relating to its oral PTH (1-34) peptide (EB613) Phase 3 program, with ASBMR-SABRE submitting a full qualification plan to the FDA to approve BMD as a surrogate endpoint for osteoporosis.